No adverse safety or virological changes two years following vorinostat in HIV-infected individuals on antiretroviral therapy.
Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DF, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR
HIV + AIDSIncreases in Caesarean Delivery Rates and Change of Perinatal Outcomes in Low- and Middle-Income Countries: A Hospital-Level Analysis of Two WHO Surveys.
Zhao Y, Zhang J, Zamora J, Vogel JP, Souza JP, Jayaratne K, Ganchimeg T, Ortiz-Panozo E, Hernandez B, Oladapo OT, Torloni MR, Morisaki N, Mori R, Pileggi-Castro C, Tunçalp Ö, Shen X, Betrán AP